JP2020510698A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020510698A5 JP2020510698A5 JP2019568815A JP2019568815A JP2020510698A5 JP 2020510698 A5 JP2020510698 A5 JP 2020510698A5 JP 2019568815 A JP2019568815 A JP 2019568815A JP 2019568815 A JP2019568815 A JP 2019568815A JP 2020510698 A5 JP2020510698 A5 JP 2020510698A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- polypeptide
- amino acid
- hla class
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 170
- 102000004196 processed proteins & peptides Human genes 0.000 claims 160
- 229920001184 polypeptide Polymers 0.000 claims 155
- 125000003275 alpha amino acid group Chemical group 0.000 claims 74
- 210000001744 T-lymphocyte Anatomy 0.000 claims 59
- 239000000427 antigen Substances 0.000 claims 46
- 102000036639 antigens Human genes 0.000 claims 46
- 108091007433 antigens Proteins 0.000 claims 46
- 238000000034 method Methods 0.000 claims 34
- 239000004480 active ingredient Substances 0.000 claims 30
- 239000008194 pharmaceutical composition Substances 0.000 claims 27
- 239000012634 fragment Substances 0.000 claims 24
- 206010028980 Neoplasm Diseases 0.000 claims 18
- 201000011510 cancer Diseases 0.000 claims 18
- 230000005867 T cell response Effects 0.000 claims 16
- 210000004027 cell Anatomy 0.000 claims 16
- 230000004044 response Effects 0.000 claims 15
- 150000001413 amino acids Chemical class 0.000 claims 14
- 230000002163 immunogen Effects 0.000 claims 10
- 210000002443 helper t lymphocyte Anatomy 0.000 claims 9
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 8
- 230000028993 immune response Effects 0.000 claims 8
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 8
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 7
- 238000011282 treatment Methods 0.000 claims 7
- 208000023275 Autoimmune disease Diseases 0.000 claims 6
- 230000001939 inductive effect Effects 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 241000700605 Viruses Species 0.000 claims 3
- 230000002411 adverse Effects 0.000 claims 3
- 239000013566 allergen Substances 0.000 claims 3
- 239000003085 diluting agent Substances 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 244000052769 pathogen Species 0.000 claims 3
- 239000003755 preservative agent Substances 0.000 claims 3
- 230000002335 preservative effect Effects 0.000 claims 3
- 230000006472 autoimmune response Effects 0.000 claims 2
- -1 carrier Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 1
- 230000001627 detrimental effect Effects 0.000 claims 1
- 238000001647 drug administration Methods 0.000 claims 1
- 230000005746 immune checkpoint blockade Effects 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 238000002626 targeted therapy Methods 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17159243.9A EP3370065A1 (en) | 2017-03-03 | 2017-03-03 | Immunogenic peptides |
| EP17159242.1 | 2017-03-03 | ||
| EP17159243.9 | 2017-03-03 | ||
| EP17159242.1A EP3369431A1 (en) | 2017-03-03 | 2017-03-03 | Vaccine |
| GB1703809.2 | 2017-03-09 | ||
| GBGB1703809.2A GB201703809D0 (en) | 2017-03-09 | 2017-03-09 | Vaccine |
| PCT/EP2018/055231 WO2018158456A1 (en) | 2017-03-03 | 2018-03-02 | Personalised immunogenic peptide identification platform |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020510698A JP2020510698A (ja) | 2020-04-09 |
| JP2020510698A5 true JP2020510698A5 (enExample) | 2021-04-15 |
Family
ID=61386864
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019568814A Active JP7751374B2 (ja) | 2017-03-03 | 2018-03-02 | ペプチドワクチン |
| JP2019568816A Active JP7437939B2 (ja) | 2017-03-03 | 2018-03-02 | 集団に基づいた免疫原性ペプチドの同定のプラットフォーム |
| JP2019568815A Pending JP2020510698A (ja) | 2017-03-03 | 2018-03-02 | 個別化された免疫原性ペプチドの同定のプラットフォーム |
| JP2022197534A Pending JP2023051941A (ja) | 2017-03-03 | 2022-12-09 | ペプチドワクチン |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019568814A Active JP7751374B2 (ja) | 2017-03-03 | 2018-03-02 | ペプチドワクチン |
| JP2019568816A Active JP7437939B2 (ja) | 2017-03-03 | 2018-03-02 | 集団に基づいた免疫原性ペプチドの同定のプラットフォーム |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022197534A Pending JP2023051941A (ja) | 2017-03-03 | 2022-12-09 | ペプチドワクチン |
Country Status (16)
| Country | Link |
|---|---|
| US (9) | US20180264095A1 (enExample) |
| EP (3) | EP3589951A1 (enExample) |
| JP (4) | JP7751374B2 (enExample) |
| KR (4) | KR102549625B1 (enExample) |
| CN (4) | CN110651188B (enExample) |
| AU (3) | AU2018228786B2 (enExample) |
| BR (3) | BR112019018307A2 (enExample) |
| CA (3) | CA3054871A1 (enExample) |
| CL (4) | CL2019002533A1 (enExample) |
| CO (3) | CO2019010524A2 (enExample) |
| IL (3) | IL268920B2 (enExample) |
| MA (3) | MA47683A (enExample) |
| MX (3) | MX2019010461A (enExample) |
| SG (3) | SG11201907402SA (enExample) |
| WO (3) | WO2018158457A1 (enExample) |
| ZA (2) | ZA201904725B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016235388B2 (en) * | 2015-03-20 | 2022-02-03 | Children's National Medical Center | Generating virus or other antigen-specific T cells from a naive T cell population |
| EP3589951A1 (en) | 2017-03-03 | 2020-01-08 | Treos Bio Zrt. | Population-based immunogenic peptide identification platform |
| GB201814361D0 (en) * | 2018-09-04 | 2018-10-17 | Treos Bio Zrt | Immunogenetic cancer screening test |
| GB201814362D0 (en) * | 2018-09-04 | 2018-10-17 | Treos Bio Zrt | Composition and process for preparing vaccine |
| BR112021004071A2 (pt) | 2018-09-04 | 2021-06-01 | Treos Bio Limited | vacinas de peptídeo |
| TW202028224A (zh) * | 2018-09-17 | 2020-08-01 | 德商英麥提克生物技術股份有限公司 | B*44限制肽在抗癌免疫治療的用途和相關方法 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| TW202039535A (zh) * | 2018-12-18 | 2020-11-01 | 德商英麥提克生物技術股份有限公司 | B*08限制肽和肽組合物抗癌免疫治療和相關方法 |
| EP4100051A2 (en) * | 2020-02-07 | 2022-12-14 | ISA Pharmaceuticals B.V. | Treatment of hpv-related diseases |
| KR102159921B1 (ko) * | 2020-03-24 | 2020-09-25 | 주식회사 테라젠바이오 | 펩타이드 서열 및 hla 대립유전자 서열을 이용하여 신생항원을 예측하는 방법 및 컴퓨터 프로그램 |
| US20230158137A1 (en) | 2020-04-03 | 2023-05-25 | Peptc Vaccines Limited | Coronavirus vaccine |
| GB202004974D0 (en) | 2020-04-03 | 2020-05-20 | Treos Bio Ltd | Coronavirus vaccine |
| CA3155533C (en) * | 2020-04-20 | 2025-02-11 | NEC Laboratories Europe GmbH | METHOD AND SYSTEM FOR THE DESIGN OF OPTIMAL VACCINE |
| CN112048001B (zh) * | 2020-09-08 | 2022-04-05 | 南方科技大学 | 一种肿瘤新生抗原多肽及其应用 |
| KR102278727B1 (ko) * | 2020-09-16 | 2021-07-19 | 주식회사 테라젠바이오 | 대상 암 조직 및 세포 유리형 dna 유래 펩타이드 서열 및 hla 클래스 ii 대립유전자 서열을 이용하여 신생항원을 예측하는 방법 및 컴퓨터 프로그램 |
| JP7627826B2 (ja) | 2021-08-10 | 2025-02-07 | 日本電気株式会社 | 情報処理システム及び情報処理方法 |
| TWI898159B (zh) | 2021-10-04 | 2025-09-21 | 日商日本電氣股份有限公司 | 管理方法、管理系統及電子健康紀錄系統 |
| WO2023059606A1 (en) * | 2021-10-06 | 2023-04-13 | Cancervax, Inc. | Methods and compositions for cancer treatment |
| US20250297036A1 (en) * | 2022-04-27 | 2025-09-25 | POSTECH Research and Business Development Foundation | Method for constructing hotspot-derived peptide-nucleic acid hybrid molecules on basis of in vitro selection |
| CN115785203B (zh) * | 2022-06-10 | 2024-03-12 | 河北博海生物工程开发有限公司 | 肺癌特异性分子靶标10及其用途 |
| JPWO2024038510A1 (enExample) | 2022-08-17 | 2024-02-22 | ||
| GB202216453D0 (en) | 2022-11-04 | 2022-12-21 | Lisziewicz Julianna | Identification of antigens which induce t-cell responses |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
| AU2203797A (en) | 1996-03-11 | 1997-10-01 | Epimmune, Inc. | Peptides with increased binding affinity for hla molecules |
| US6617434B1 (en) * | 1996-05-31 | 2003-09-09 | North Shore Long Island Jewish Research Institute | Identificiaton of differentially methylated and mutated nucleic acids |
| US20030148463A1 (en) | 1997-04-14 | 2003-08-07 | Micromet Ag | Novel method for the production of anti-human antigen receptors and uses thereof |
| KR100663319B1 (ko) * | 1997-04-14 | 2007-01-02 | 마이크로메트 에이지 | 인간 17-1에이항원에 대해 특이성을 갖는 인간항체 및 그용도 |
| FR2791895B1 (fr) | 1999-03-23 | 2001-06-15 | Pasteur Merieux Serums Vacc | Utilisation de trehalose pour stabiliser un vaccin liquide |
| AUPQ776100A0 (en) | 2000-05-26 | 2000-06-15 | Australian National University, The | Synthetic molecules and uses therefor |
| US6673580B2 (en) | 2000-10-27 | 2004-01-06 | Genentech, Inc. | Identification and modification of immunodominant epitopes in polypeptides |
| US7892559B2 (en) | 2002-01-30 | 2011-02-22 | Survac Aps | Survivin-derived peptides and use thereof |
| WO2004022709A2 (en) | 2002-09-06 | 2004-03-18 | Mannkind Corporation | Epitope sequences |
| GB0228900D0 (en) | 2002-12-11 | 2003-01-15 | Ml Lab Plc | Cancer Immunotherapy |
| CA2522379C (en) | 2003-04-10 | 2012-10-23 | Chiron Corporation | The severe acute respiratory syndrome coronavirus |
| US20050084913A1 (en) * | 2003-04-22 | 2005-04-21 | Maxygen, Inc. | Novel tumor-associated antigens |
| US20050100883A1 (en) | 2003-11-12 | 2005-05-12 | Wang Chang Y. | Peptide-based diagnostic reagents for SARS |
| CA2554001A1 (en) * | 2004-01-20 | 2005-07-28 | Aichi Prefecture | Epitope/peptide recognized by hla-a2402-restricted ep-cam-specific ctl and use of the same |
| CA2566506A1 (en) | 2004-06-01 | 2005-12-15 | Innogenetics N.V. | Peptides for inducing a ctl and/or htl response to hepatitis c virus |
| WO2006080142A1 (ja) | 2005-01-25 | 2006-08-03 | Nec Corporation | Ｈｌａ結合性ペプチド、それをコードするｄｎａ断片および組み換えベクター |
| RU2396088C2 (ru) | 2005-02-04 | 2010-08-10 | СУРВАК АпС | Вакцина на основе пептидов сурвивина |
| CN100402554C (zh) * | 2005-02-25 | 2008-07-16 | 李玉新 | 睾丸特异性蛋白50人源抗体的制备及用途 |
| FR2891462B1 (fr) | 2005-09-30 | 2009-10-16 | Commissariat Energie Atomique | Epitopes t cd4+ de la survivine et leurs applications |
| GB0520067D0 (en) | 2005-10-01 | 2005-11-09 | Cancer Rec Tech Ltd | Treatment of cancer |
| CA2665816C (en) | 2006-09-21 | 2016-07-12 | Vaxil Biotherapeutics Ltd. | Antigen specific multi epitope vaccines |
| CA2700573C (en) | 2006-09-26 | 2016-11-22 | Cedars-Sinai Medical Center | Cancer stem cell antigen vaccines and methods |
| EP2361930A3 (en) | 2007-03-26 | 2011-10-26 | Dako Denmark A/S | Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases |
| EP2042600A1 (en) * | 2007-09-28 | 2009-04-01 | Commissariat A L'energie Atomique | A public and immunogenic CD4+ T Cell epitope of the hiv tat protein and its applications |
| CN101981187A (zh) | 2008-03-31 | 2011-02-23 | 株式会社生物免疫平衡 | MHC Ⅱ类分子提呈的存活蛋白(Survivin)的部分肽及其利用方法 |
| PL2119726T5 (pl) | 2008-05-14 | 2018-04-30 | Immatics Biotechnologies Gmbh | Nowe i silne peptydy MHC klasy II pochodzące z surwiwiny i neurokanu |
| TW201008574A (en) * | 2008-08-19 | 2010-03-01 | Oncotherapy Science Inc | INHBB epitope peptides and vaccines containing the same |
| WO2010037395A2 (en) | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
| GB0818065D0 (en) * | 2008-10-02 | 2008-11-05 | Cancer Rec Tech Ltd | Immunogenic peptides and uses thereof |
| US20120244145A1 (en) * | 2009-11-16 | 2012-09-27 | Duke University | Enhanced immunological responses |
| GB201004575D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers |
| US20170039314A1 (en) * | 2010-03-23 | 2017-02-09 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
| WO2012051282A2 (en) | 2010-10-14 | 2012-04-19 | The Ohio State University Research Foundation | Piwil2-like (pl2l) proteins-targeted cancer diagnosis and therapy |
| EP2745845A1 (en) * | 2012-12-19 | 2014-06-25 | Centre Hospitalier Universitaire de Bordeaux | A method for preventing or treating an HIV infection |
| ES2832546T3 (es) * | 2013-01-15 | 2021-06-10 | Memorial Sloan Kettering Cancer Center | Péptidos WT-1 inmunogénicos y métodos de uso de los mismos |
| WO2014180490A1 (en) | 2013-05-10 | 2014-11-13 | Biontech Ag | Predicting immunogenicity of t cell epitopes |
| GB201315946D0 (en) | 2013-09-06 | 2013-10-23 | Immune Targeting Systems Its Ltd | Oncology vaccine |
| CN105828834A (zh) * | 2013-11-05 | 2016-08-03 | 同源生物服务股份有限公司 | 检查点抑制剂和治疗剂的组合以治疗癌症 |
| US9884895B2 (en) | 2014-03-20 | 2018-02-06 | The University Of North Carolina At Chapel Hill | Methods and compositions for chimeric coronavirus spike proteins |
| US10111948B2 (en) | 2014-04-25 | 2018-10-30 | Tria Bioscience Corp. | Synthetic hapten carrier compositions and methods |
| WO2016040900A1 (en) | 2014-09-14 | 2016-03-17 | Washington University | Personalized cancer vaccines and methods therefor |
| US10317402B2 (en) * | 2014-12-03 | 2019-06-11 | Verik Bio, Inc. | Identification, selection and use of high curative potential T cell epitopes |
| TW201636358A (zh) * | 2014-12-09 | 2016-10-16 | 腫瘤療法 科學股份有限公司 | 對於ｔｈ１細胞之ｇｐｃ３抗原決定位胜肽及含此之疫苗 |
| WO2016172722A1 (en) | 2015-04-23 | 2016-10-27 | Nantomics, Llc | Cancer neoepitopes |
| US11090332B2 (en) | 2015-05-21 | 2021-08-17 | Regen BioPharma, Inc. | Antigen specific mRNA cellular cancer vaccines |
| EP3362930A4 (en) | 2015-10-12 | 2019-06-19 | Nantomics, LLC | SYSTEMS, COMPOSITIONS, AND METHODS FOR DISCOVERING MSI AND NEOEPPITOPES THAT PROVIDE SENSITIVITY TO IMMUNE CONTROL POINTS |
| GB201604755D0 (en) | 2016-03-21 | 2016-05-04 | Vaxeal Res Sas | Immunogenic compositions |
| CA3039541A1 (en) | 2016-10-07 | 2018-04-12 | Board Of Regents,The University Of Texas System | Hla-restricted vgll1 peptides and use thereof |
| TWI796314B (zh) | 2017-01-27 | 2023-03-21 | 德商英麥提克生物技術股份有限公司 | 用於卵巢癌和其他癌症免疫治療的新型肽和肽組合物 |
| EP3369431A1 (en) | 2017-03-03 | 2018-09-05 | Treos Bio Kft | Vaccine |
| EP3589951A1 (en) * | 2017-03-03 | 2020-01-08 | Treos Bio Zrt. | Population-based immunogenic peptide identification platform |
| EP3370065A1 (en) | 2017-03-03 | 2018-09-05 | Treos Bio Kft | Immunogenic peptides |
| TWI837109B (zh) | 2017-12-28 | 2024-04-01 | 美商磨石生物公司 | 靶向共有抗原之抗原結合蛋白 |
| JP2021526365A (ja) | 2018-05-18 | 2021-10-07 | チルドレンズ ナショナル メディカル センターＣｈｉｌｄｒｅｎ’Ｓ Ｎａｔｉｏｎａｌ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ | 改善された標的化ｔ細胞療法 |
| US20210213066A1 (en) | 2018-05-18 | 2021-07-15 | Children's National Medical Center | Improved cell therapy compositions for hematopoietic stem cell transplant patients |
| GB201814362D0 (en) | 2018-09-04 | 2018-10-17 | Treos Bio Zrt | Composition and process for preparing vaccine |
| GB201814361D0 (en) | 2018-09-04 | 2018-10-17 | Treos Bio Zrt | Immunogenetic cancer screening test |
| BR112021004071A2 (pt) | 2018-09-04 | 2021-06-01 | Treos Bio Limited | vacinas de peptídeo |
| US20220062342A1 (en) | 2019-01-07 | 2022-03-03 | Children's National Medical Center | Improved targeted t-cell therapy for treatment of multiple myeloma |
| CA3126066A1 (en) | 2019-01-07 | 2020-07-16 | Children's National Medical Center | Ex vivo activated t-lymphocytic compositions and methods of using the same |
| GB202004974D0 (en) | 2020-04-03 | 2020-05-20 | Treos Bio Ltd | Coronavirus vaccine |
-
2018
- 2018-03-02 EP EP18710392.4A patent/EP3589951A1/en active Pending
- 2018-03-02 IL IL268920A patent/IL268920B2/en unknown
- 2018-03-02 JP JP2019568814A patent/JP7751374B2/ja active Active
- 2018-03-02 CA CA3054871A patent/CA3054871A1/en active Pending
- 2018-03-02 WO PCT/EP2018/055232 patent/WO2018158457A1/en not_active Ceased
- 2018-03-02 CN CN201880014727.1A patent/CN110651188B/zh active Active
- 2018-03-02 US US15/910,965 patent/US20180264095A1/en not_active Abandoned
- 2018-03-02 EP EP18707725.0A patent/EP3589310A1/en active Pending
- 2018-03-02 AU AU2018228786A patent/AU2018228786B2/en active Active
- 2018-03-02 MA MA047683A patent/MA47683A/fr unknown
- 2018-03-02 EP EP18707724.3A patent/EP3589954A1/en active Pending
- 2018-03-02 KR KR1020197029092A patent/KR102549625B1/ko active Active
- 2018-03-02 JP JP2019568816A patent/JP7437939B2/ja active Active
- 2018-03-02 MX MX2019010461A patent/MX2019010461A/es unknown
- 2018-03-02 CA CA3054861A patent/CA3054861A1/en active Pending
- 2018-03-02 MX MX2019010460A patent/MX2019010460A/es unknown
- 2018-03-02 CN CN202411399993.4A patent/CN119371510A/zh active Pending
- 2018-03-02 US US15/910,930 patent/US20180264094A1/en not_active Abandoned
- 2018-03-02 CN CN201880014739.4A patent/CN110621334A/zh active Pending
- 2018-03-02 SG SG11201907402SA patent/SG11201907402SA/en unknown
- 2018-03-02 SG SG11201907524UA patent/SG11201907524UA/en unknown
- 2018-03-02 AU AU2018226566A patent/AU2018226566B2/en active Active
- 2018-03-02 KR KR1020197029093A patent/KR102723248B1/ko active Active
- 2018-03-02 MA MA047677A patent/MA47677A/fr unknown
- 2018-03-02 WO PCT/EP2018/055231 patent/WO2018158456A1/en not_active Ceased
- 2018-03-02 IL IL268919A patent/IL268919B2/en unknown
- 2018-03-02 BR BR112019018307-8A patent/BR112019018307A2/pt unknown
- 2018-03-02 AU AU2018228785A patent/AU2018228785B2/en active Active
- 2018-03-02 JP JP2019568815A patent/JP2020510698A/ja active Pending
- 2018-03-02 MA MA047678A patent/MA47678A/fr unknown
- 2018-03-02 KR KR1020197029094A patent/KR102591136B1/ko active Active
- 2018-03-02 KR KR1020247034375A patent/KR20240156643A/ko active Pending
- 2018-03-02 MX MX2019010459A patent/MX2019010459A/es unknown
- 2018-03-02 US US15/910,988 patent/US10213497B2/en active Active
- 2018-03-02 CA CA3054866A patent/CA3054866A1/en active Pending
- 2018-03-02 SG SG11201906765UA patent/SG11201906765UA/en unknown
- 2018-03-02 BR BR112019018313A patent/BR112019018313A2/pt unknown
- 2018-03-02 CN CN201880014745.XA patent/CN110651189B/zh active Active
- 2018-03-02 BR BR112019018312-4A patent/BR112019018312A2/pt unknown
- 2018-03-02 WO PCT/EP2018/055230 patent/WO2018158455A1/en not_active Ceased
-
2019
- 2019-01-10 US US16/244,497 patent/US11213578B2/en active Active
- 2019-07-18 ZA ZA2019/04725A patent/ZA201904725B/en unknown
- 2019-07-18 ZA ZA2019/04723A patent/ZA201904723B/en unknown
- 2019-08-26 IL IL268917A patent/IL268917B2/en unknown
- 2019-09-03 CL CL2019002533A patent/CL2019002533A1/es unknown
- 2019-09-03 CL CL2019002534A patent/CL2019002534A1/es unknown
- 2019-09-03 CL CL2019002532A patent/CL2019002532A1/es unknown
- 2019-09-26 CO CONC2019/0010524A patent/CO2019010524A2/es unknown
- 2019-09-26 CO CONC2019/0010503A patent/CO2019010503A2/es unknown
- 2019-09-27 CO CONC2019/0010698A patent/CO2019010698A2/es unknown
-
2021
- 2021-09-17 US US17/448,020 patent/US20220031823A1/en not_active Abandoned
- 2021-11-09 US US17/454,225 patent/US20220072114A1/en not_active Abandoned
- 2021-12-22 US US17/645,737 patent/US11426452B2/en active Active
- 2021-12-22 US US17/645,741 patent/US11628211B2/en active Active
-
2022
- 2022-10-14 CL CL2022002836A patent/CL2022002836A1/es unknown
- 2022-12-09 JP JP2022197534A patent/JP2023051941A/ja active Pending
-
2023
- 2023-02-08 US US18/166,420 patent/US20230405100A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020510698A5 (enExample) | ||
| Michels da Silva et al. | Inflammatory and molecular pathways in heart failure—ischemia, HFpEF and transthyretin cardiac amyloidosis | |
| Shahid et al. | Role of monocytes in heart failure and atrial fibrillation | |
| LeBrasseur et al. | Cellular senescence and the biology of aging, disease, and frailty | |
| EP3552126B1 (en) | Systems and methods for sequencing t cell receptors and uses thereof | |
| Green et al. | Persistence of mild, early inflammatory arthritis: the importance of disease duration, rheumatoid factor, and the shared epitope | |
| Liakouli et al. | Systemic sclerosis interstitial lung disease: unmet needs and potential solutions | |
| Lin et al. | Intestinal strictures in Crohn’s disease: a 2021 update | |
| US20230026789A1 (en) | Methods, systems, and tools for longevity-related applications | |
| Ohlow et al. | Therapeutic effect of immunoadsorption and subsequent immunoglobulin substitution in patients with dilated cardiomyopathy: Results from the observational prospective Bad Berka Registry | |
| Park et al. | Interleukin 13–and interleukin 17A–induced pulmonary hypertension phenotype due to inhalation of antigen and fine particles from air pollution | |
| JP2018502828A (ja) | Ｐｄ−１遮断による免疫療法の癌奏効の決定因子 | |
| Chin et al. | Leptospirosis in human: Biomarkers in host immune responses | |
| Rice et al. | A proteome-derived longitudinal pharmacodynamic biomarker for diffuse systemic sclerosis skin | |
| US20150233939A1 (en) | Methods and compositions for biomarkers of fatigue | |
| Spellman et al. | Scoring HLA class I mismatches by HistoCheck does not predict clinical outcome in unrelated hematopoietic stem cell transplantation | |
| Khalid et al. | Impact of diabetes mellitus on clinico-laboratory characteristics and in-hospital clinical outcomes among patients with myocardial infarction | |
| Wu et al. | Effect of anti‐TNF antibodies on clinical response in rheumatoid arthritis patients: a meta‐analysis | |
| Kapniari et al. | Investigating the link between psoriasis and cardiovascular disease: current evidence, therapeutic implications and perspectives | |
| JP2018527661A (ja) | 有意性が未知のバリアントに優先順位をつけるシステム及び方法 | |
| Pedicino et al. | Restricted T-cell repertoire in the epicardial adipose tissue of non-ST segment elevation myocardial infarction patients | |
| Lupieri et al. | Rheumatic heart valve disease: navigating the challenges of an overlooked autoimmune disorder | |
| Heinz-Peter et al. | Dilated cardiomyopathy (primer) | |
| Song et al. | A synthetic SARS-CoV-2-derived T-cell and B-cell peptide cocktail elicits full protection against lethal Omicron BA. 1 infection in H11-K18-hACE2 mice | |
| Maruyama et al. | Treatment patterns in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma post covalent Bruton tyrosine kinase inhibitor treatment: a Japanese claims database study |